Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.<font color=red>.<font size=4>.SDEV developing a better "Taser" product:</font color></font size>.
BUSINESS
Security Devices is developing a wireless, non-lethal electrical stun
weapon (referred to in this prospectus as a "WERS") for use in law enforcement,
military, professional and home security.
There are three basic categories of non-lethal weapons:
1. Impact Devices
o Baton
o Rubber Bullet
o Soft Projectile
2. Chemical Agents
o Pepper Spray
o Tear Gas
o CS
7
3. Other Types
o Electrical Devices, such as the TASER(R) and Stun Guns
o Capture Net
o Flash/Bang Grenade
o Head/Neck Restraint
The safety and effectiveness implications of all non-lethal options are
under constant scrutiny and evaluation. Law enforcement agencies, as well as
private citizens, are under pressure to reduce the incidence of lethal force in
both apprehension and defense. A number of elements contribute to the ever
growing need for a more effective, non-lethal weapon:
o Excessive use of firearms by the police.
o Excessive use of firearms for self defence.
o Increased incidence of serious injury and death from attempted
defensive actions.
o Increased liability claims against police.
o Increased utilization of military forces for peace keeping, crowd
control and homeland security.
The WERS uses an electro-muscular disruption technology to induce
involuntary muscle contractions causing the subject to be temporarily
incapacitated. Electro-muscular disruption devices include traditional stun
guns, TASERS(R), and Stinger(R) handheld projectile stun guns.
The WERS is similar to conventional, widely used electrical weapons, with
two major differences:
1. WERS is wireless. Rounds fired from WERS are not connected to the
firing device by wires. This feature provides added range and less
likelihood of interference from moving objects and people, both
accidental and intentional.
2. WERS has a far greater firing range than devices currently on the
market. Its wireless round will be able to temporarily incapacitate
violent offenders and combatants from a distance as far as 75 metres
or greater depending on powder charge and firing conditions. This
range is up to ten times better than most competing firing devices,
providing significant safety advantages for military and law
enforcement personnel. In contrast, Stun Gun operators must be in
direct physical contact with combatants, placing the enforcement
officer in potential danger.
Security Devices plan to develop both a Long Range and a Short Range
version of the WERS.
The Long Range WERS will have an accurate firing distance of up to 75
meters and can be fired from conventional weapons, such as single shot riot
rifles or shotguns.
The Short Range WERS will have a safe firing range of 2 to 10 meters and
will be fired from a proprietary system powered by a pressurized air cartridge.
.<font color=red><font size=4>.SDEV developing a better "Taser" product:</font color></font size>.
BUSINESS
Security Devices is developing a wireless, non-lethal electrical stun
weapon (referred to in this prospectus as a "WERS") for use in law enforcement,
military, professional and home security.
There are three basic categories of non-lethal weapons:
1. Impact Devices
o Baton
o Rubber Bullet
o Soft Projectile
2. Chemical Agents
o Pepper Spray
o Tear Gas
o CS
7
3. Other Types
o Electrical Devices, such as the TASER(R) and Stun Guns
o Capture Net
o Flash/Bang Grenade
o Head/Neck Restraint
The safety and effectiveness implications of all non-lethal options are
under constant scrutiny and evaluation. Law enforcement agencies, as well as
private citizens, are under pressure to reduce the incidence of lethal force in
both apprehension and defense. A number of elements contribute to the ever
growing need for a more effective, non-lethal weapon:
o Excessive use of firearms by the police.
o Excessive use of firearms for self defence.
o Increased incidence of serious injury and death from attempted
defensive actions.
o Increased liability claims against police.
o Increased utilization of military forces for peace keeping, crowd
control and homeland security.
The WERS uses an electro-muscular disruption technology to induce
involuntary muscle contractions causing the subject to be temporarily
incapacitated. Electro-muscular disruption devices include traditional stun
guns, TASERS(R), and Stinger(R) handheld projectile stun guns.
The WERS is similar to conventional, widely used electrical weapons, with
two major differences:
1. WERS is wireless. Rounds fired from WERS are not connected to the
firing device by wires. This feature provides added range and less
likelihood of interference from moving objects and people, both
accidental and intentional.
2. WERS has a far greater firing range than devices currently on the
market. Its wireless round will be able to temporarily incapacitate
violent offenders and combatants from a distance as far as 75 metres
or greater depending on powder charge and firing conditions. This
range is up to ten times better than most competing firing devices,
providing significant safety advantages for military and law
enforcement personnel. In contrast, Stun Gun operators must be in
direct physical contact with combatants, placing the enforcement
officer in potential danger.
Security Devices plan to develop both a Long Range and a Short Range
version of the WERS.
The Long Range WERS will have an accurate firing distance of up to 75
meters and can be fired from conventional weapons, such as single shot riot
rifles or shotguns.
The Short Range WERS will have a safe firing range of 2 to 10 meters and
will be fired from a proprietary system powered by a pressurized air cartridge.
Thanks 4 SDEV..... I'm in da' money!!!!!!
SDEV developing a better "Taser" product:
BUSINESS
Security Devices is developing a wireless, non-lethal electrical stun
weapon (referred to in this prospectus as a "WERS") for use in law enforcement,
military, professional and home security.
There are three basic categories of non-lethal weapons:
1. Impact Devices
o Baton
o Rubber Bullet
o Soft Projectile
2. Chemical Agents
o Pepper Spray
o Tear Gas
o CS
7
3. Other Types
o Electrical Devices, such as the TASER(R) and Stun Guns
o Capture Net
o Flash/Bang Grenade
o Head/Neck Restraint
The safety and effectiveness implications of all non-lethal options are
under constant scrutiny and evaluation. Law enforcement agencies, as well as
private citizens, are under pressure to reduce the incidence of lethal force in
both apprehension and defense. A number of elements contribute to the ever
growing need for a more effective, non-lethal weapon:
o Excessive use of firearms by the police.
o Excessive use of firearms for self defence.
o Increased incidence of serious injury and death from attempted
defensive actions.
o Increased liability claims against police.
o Increased utilization of military forces for peace keeping, crowd
control and homeland security.
The WERS uses an electro-muscular disruption technology to induce
involuntary muscle contractions causing the subject to be temporarily
incapacitated. Electro-muscular disruption devices include traditional stun
guns, TASERS(R), and Stinger(R) handheld projectile stun guns.
The WERS is similar to conventional, widely used electrical weapons, with
two major differences:
1. WERS is wireless. Rounds fired from WERS are not connected to the
firing device by wires. This feature provides added range and less
likelihood of interference from moving objects and people, both
accidental and intentional.
2. WERS has a far greater firing range than devices currently on the
market. Its wireless round will be able to temporarily incapacitate
violent offenders and combatants from a distance as far as 75 metres
or greater depending on powder charge and firing conditions. This
range is up to ten times better than most competing firing devices,
providing significant safety advantages for military and law
enforcement personnel. In contrast, Stun Gun operators must be in
direct physical contact with combatants, placing the enforcement
officer in potential danger.
Security Devices plan to develop both a Long Range and a Short Range
version of the WERS.
The Long Range WERS will have an accurate firing distance of up to 75
meters and can be fired from conventional weapons, such as single shot riot
rifles or shotguns.
The Short Range WERS will have a safe firing range of 2 to 10 meters and
will be fired from a proprietary system powered by a pressurized air cartridge.
GBRC +500%...... VASO is on the hit list next. Cash out the GWGO's, it has peaked. Also, look for a trap on SLJB.
It's cash out time!
Good Trading!
***** FGFC and VASO are set for nice runs.
Wooooooooo DPER is +66.67%.....ChaChing!!!!
Cash that GWGO out, it looks like it has peaked. Keep FGFC on the radar.... a spike is due.
Good Trading!
GBRC +500%...... LOL!!!!!!!
Look at the spread..... .25 x 1.20
I wish someone would light the fuse on VASO, God knows I cant......hehehe!
Good Trading!
It's all messed up. Both the left and the right have it screwed up. Take for example life and death. The left says it's ok to kill unborn children and to spare someone with a death sentence. The right says spare the unborn children and hang the guilty. In the end they are the same and have opposing views on who to kill. Anyone ever wonder why there can be billions on top of billions spent on war and then when the troops come home the funding stops. The money spent on the war could have been spent in better places such as lifting man up while he is down rather than kicking him while he is down. This is our world. The instant Bush was elected the wise thing to do was let it all ride on oil, ore, and defense contractors. The instant the Dem's get elected the smart thing to do is buy biotech, healthcare, and defense contractors. Business calls, everyone have a good day.
Good Trading!
VASO due to pop eom.
VASO is my dog of the year. I own from .18 down and it is .13 now......ouch! It would be nice to see GWGO pop.... place FGFC on that list too. PGNX is smokin' this year.
Good Trading!
Benefits of Vasomedical's EECP Therapy in Heart Failure Presented at the 10th Annual HFSA Scientific Meeting; Ventricular Function, Exercise Capacity, Symptom Status, Quality of Life All Improve
WESTBURY, N.Y.--(BUSINESS WIRE)----Vasomedical, Inc. (OTCBB: VASO), a leader in noninvasive management of cardiovascular diseases, announced today three presentations highlighting the benefits of EECP(R) therapy in patients with heart failure were made at the 10th Annual Heart Failure Society of America Scientific (HFSA) Meeting held in Seattle, Washington, September 10-13.
Investigators at the Escorts Heart Institute and Research Centre, New Delhi, India, presented data demonstrating that heart failure patients were able to double their exercise capacity following a course of EECP therapy and maintain the benefit at one-year follow-up, along with significant improvements in quality of life. Dr. Anil K. Gothwal and colleagues also used echocardiography to objectively assess function and size of the heart's main pumping chamber, the left ventricle, showing significant improvement and confirming some of the physiologic changes achievable with EECP therapy.
Susan F. Neill, Citrus Cardiology Consultants, Inverness, FL, and Dr. Michael E. McIvor, St. Petersburg Heart Center, St. Petersburg, FL, presented data from a cohort of 53 adult patients with systolic heart failure. Their results also showed significant improvements in symptom status, exercise capacity, quality of life and ventricular function. Moreover, circulating levels of BNP (brain natriuretic peptide), a marker of heart failure progression, were also shown to significantly improve upon completion of therapy.
VASOMEDICAL INC
[Stock Ticker Chart]
OTCBB:VASO
Updated: 15:59 ET
0.128 -0.007
William Lawson, M.D., FACC, University of Stony Brook Medical Center, Stony Brook, NY, presented data from the International EECP Patient Registry demonstrating that EECP therapy is equally effective in diabetic and non-diabetic patients suffering from angina and heart failure. Both diabetic and non-diabetic heart failure patients received the same benefits from EECP treatment, with improvement in at least one class in both Canadian Cardiovascular Society (CCS) and New York Heart Association (NYHA) classifications, decreases in weekly angina episodes and nitroglycerin use, and improvement in quality of life scores. Physicians commonly use CCS and NYHA classifications to define the impact of angina and/or heart failure symptoms respectively on ability to function.
"A patient with heart failure suffers tremendously from his or her symptoms and from limitations on activity and lifestyle. EECP therapy can lessen debilitating and discouraging symptoms, and increase the ability to engage in social and physical activity, even in patients receiving optimal medical therapy. We believe that the PEECH trial demonstrated this in a definitive way and the presentations made at the HFSA conference continue to highlight the dramatic improvements that can be achieved with this cost-effective, noninvasive therapy," commented Thomas Glover, president and chief executive officer of Vasomedical.
About EECP(R) Therapy
EECP external counterpulsation therapy is typically given in a doctor's office or outpatient clinic in 35 one-hour sessions over 4 to 7 weeks. Patients recline on a contoured treatment table and their calves, lower thighs and upper thighs are wrapped in a pneumatic cuff set. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting and deflates the cuffs just before the next heartbeat. The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle and other organs and decreases the heart's workload, creating a greater oxygen supply for the heart muscle while lowering its need for oxygen. Additionally, EECP therapy improves function of the endothelium, the inner lining of blood vessels throughout the body, thereby lessening resistance to blood flow.
About Vasomedical, Inc.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently used for chronic stable angina and heart failure. Indications for use include stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and improves systemic vascular function. The Company provides hospitals, clinics and private practices with EECP equipment, treatment guidance and a staff training and equipment maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com. EECP is a registered trademark for Vasomedical's enhanced external counterpulsation systems.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports, including the ability of the Company to continue as a going concern. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Vasomedical, Inc. Thomas Glover or Thomas Varricchione, 516-997-4600 or Investor Relations: 516-997-4600 ext. 790 investorrelations@vasomedical.com
09/19/2006 14:16
Benefits of Vasomedical's EECP Therapy in Heart Failure Presented at the 10th Annual HFSA Scientific Meeting; Ventricular Function, Exercise Capacity, Symptom Status, Quality of Life All Improve
WESTBURY, N.Y.--(BUSINESS WIRE)----Vasomedical, Inc. (OTCBB: VASO), a leader in noninvasive management of cardiovascular diseases, announced today three presentations highlighting the benefits of EECP(R) therapy in patients with heart failure were made at the 10th Annual Heart Failure Society of America Scientific (HFSA) Meeting held in Seattle, Washington, September 10-13.
Investigators at the Escorts Heart Institute and Research Centre, New Delhi, India, presented data demonstrating that heart failure patients were able to double their exercise capacity following a course of EECP therapy and maintain the benefit at one-year follow-up, along with significant improvements in quality of life. Dr. Anil K. Gothwal and colleagues also used echocardiography to objectively assess function and size of the heart's main pumping chamber, the left ventricle, showing significant improvement and confirming some of the physiologic changes achievable with EECP therapy.
Susan F. Neill, Citrus Cardiology Consultants, Inverness, FL, and Dr. Michael E. McIvor, St. Petersburg Heart Center, St. Petersburg, FL, presented data from a cohort of 53 adult patients with systolic heart failure. Their results also showed significant improvements in symptom status, exercise capacity, quality of life and ventricular function. Moreover, circulating levels of BNP (brain natriuretic peptide), a marker of heart failure progression, were also shown to significantly improve upon completion of therapy.
VASOMEDICAL INC
[
Stock Ticker Chart]
OTCBB:VASO
Updated: 15:59 ET
0.128 -0.007
William Lawson, M.D., FACC, University of Stony Brook Medical Center, Stony Brook, NY, presented data from the International EECP Patient Registry demonstrating that EECP therapy is equally effective in diabetic and non-diabetic patients suffering from angina and heart failure. Both diabetic and non-diabetic heart failure patients received the same benefits from EECP treatment, with improvement in at least one class in both Canadian Cardiovascular Society (CCS) and New York Heart Association (NYHA) classifications, decreases in weekly angina episodes and nitroglycerin use, and improvement in quality of life scores. Physicians commonly use CCS and NYHA classifications to define the impact of angina and/or heart failure symptoms respectively on ability to function.
"A patient with heart failure suffers tremendously from his or her symptoms and from limitations on activity and lifestyle. EECP therapy can lessen debilitating and discouraging symptoms, and increase the ability to engage in social and physical activity, even in patients receiving optimal medical therapy. We believe that the PEECH trial demonstrated this in a definitive way and the presentations made at the HFSA conference continue to highlight the dramatic improvements that can be achieved with this cost-effective, noninvasive therapy," commented Thomas Glover, president and chief executive officer of Vasomedical.
About EECP(R) Therapy
EECP external counterpulsation therapy is typically given in a doctor's office or outpatient clinic in 35 one-hour sessions over 4 to 7 weeks. Patients recline on a contoured treatment table and their calves, lower thighs and upper thighs are wrapped in a pneumatic cuff set. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting and deflates the cuffs just before the next heartbeat. The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle and other organs and decreases the heart's workload, creating a greater oxygen supply for the heart muscle while lowering its need for oxygen. Additionally, EECP therapy improves function of the endothelium, the inner lining of blood vessels throughout the body, thereby lessening resistance to blood flow.
About Vasomedical, Inc.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently used for chronic stable angina and heart failure. Indications for use include stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and improves systemic vascular function. The Company provides hospitals, clinics and private practices with EECP equipment, treatment guidance and a staff training and equipment maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com. EECP is a registered trademark for Vasomedical's enhanced external counterpulsation systems.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports, including the ability of the Company to continue as a going concern. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Vasomedical, Inc. Thomas Glover or Thomas Varricchione, 516-997-4600 or Investor Relations: 516-997-4600 ext. 790 investorrelations@vasomedical.com
09/19/2006 14:16
If VASO runs, it will be this week.
Disclamer: This is a screaming strong buy.
Good Trading!
If VASO runs, it will be this week.
Disclamer: This is a screaming strong buy.
Good Trading!
If VASO runs, it will be this week.
Disclamer: This is a screaming strong buy.
Good Trading!
Yes, Yes, Yes!!!!
I have been following VASO for the last week. The hard copy of the PEECH results are due in the a.m., the online version is out now. The MM's have held the stock in a sideways position and are looking for shares. Once Monday opens expect mammoth volume. If a small percentage of the readership puts a few hundred bucks in the stock the thing would explode into the cosmos. I believe today is the last day to get cheap shares. The stock traded in the $5's a few years back. Everyone have a great weekend.
.14 x .148
Good Trading!
Yes, Yes, Yes!!!!
I have been following VASO for the last week. The hard copy of the PEECH results are due in the a.m., the online version is out now. The MM's have held the stock in a sideways position and are looking for shares. Once Monday opens expect mammoth volume. If a small percentage of the readership puts a few hundred bucks in the stock the thing would explode into the cosmos. I believe today is the last day to get cheap shares. The stock traded in the $5's a few years back. Everyone have a great weekend.
.14 x .148
Good Trading!
Yes, Yes, Yes!!!!
I have been following VASO for the last week. The hard copy of the PEECH results are due in the a.m., the online version is out now. The MM's have held the stock in a sideways position and are looking for shares. Once Monday opens expect mammoth volume. If a small percentage of the readership puts a few hundred bucks in the stock the thing would explode into the cosmos. I believe today is the last day to get cheap shares. The stock traded in the $5's a few years back. Everyone have a great weekend.
.14 x .148
Good Trading!
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology will be published on September 19th.
EECP Therapy Benefits Patients with Mild-to-Moderate Heart Failure
is Most Effective for Treating Ischemic Heart Failure Patients.
VASO is a pure gem!!!!
VASO .13 x .15
UNDER A $10 million MARKET CAP!!!
VASO is on the BB's and once was on the NASD @ $5.00+
Sept. 19th = KABOOOOOOOOOOOOOOOM!!!!!!!!!!!!!!!!!!
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology will be published on September 19th.
EECP Therapy Benefits Patients with Mild-to-Moderate Heart Failure
is Most Effective for Treating Ischemic Heart Failure Patients.
VASO is a pure gem!!!!
VASO .13 x .15
UNDER A $10 million MARKET CAP!!!
VASO is on the BB's and once was on the NASD @ $5.00+
Sept. 19th = KABOOOOOOOOOOOOOOOM!!!!!!!!!!!!!!!!!!
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology will be published on September 19th.
EECP Therapy Benefits Patients with Mild-to-Moderate Heart Failure
is Most Effective for Treating Ischemic Heart Failure Patients.
VASO is a pure gem!!!!
VASO .13 x .15
UNDER A $10 million MARKET CAP!!!
VASO is on the BB's and once was on the NASD @ $5.00+
Sept. 19th = KABOOOOOOOOOOOOOOOM!!!!!!!!!!!!!!!!!!
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology will be published on September 19th.
EECP Therapy Benefits Patients with Mild-to-Moderate Heart Failure
is Most Effective for Treating Ischemic Heart Failure Patients.
VASO is a pure gem!!!!
VASO .13 x .15
UNDER A $10 million MARKET CAP!!!
VASO is on the BB's and once was on the NASD @ $5.00+
Sept. 19th = KABOOOOOOOOOOOOOOOM!!!!!!!!!!!!!!!!!!
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology will be published on September 19th.
EECP Therapy Benefits Patients with Mild-to-Moderate Heart Failure
is Most Effective for Treating Ischemic Heart Failure Patients.
VASO is a pure gem!!!!
VASO .13 x .15
UNDER A $10 million MARKET CAP!!!
VASO is on the BB's and once was on the NASD @ $5.00+
Sept. 19th = KABOOOOOOOOOOOOOOOM!!!!!!!!!!!!!!!!!!
Lorraine from InterWest can kiss my a$$....hehe!
GVRP/MAMG......... anyone know anything new?
Only 5 days until VASO gets published:
http://66.201.236.134/export/level2.jsp?symbol=vaso&=Get+Quote
Only 5 days until VASO gets published:
http://66.201.236.134/export/level2.jsp?symbol=vaso&=Get+Quote
VASO is in the green. L2 inside:
http://66.201.236.134/export/level2.jsp?symbol=vaso&=Get+Quote
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology
WESTBURY, N.Y.--(BUSINESS WIRE)---- EECP Therapy Benefits Patients with Mild-to-Moderate Heart Failure; is Most Effective for Treating Ischemic Heart Failure Patients
Vasomedical, Inc. (OTCBB: VASO.OB), a leader in the non-invasive treatment and management of cardiovascular diseases, announced today publication of the results of the PEECH trial (Prospective Evaluation of EECP in Congestive Heart Failure) in the Journal of the American College of Cardiology. The report, entitled "Enhanced External Counterpulsation Improves Exercise Tolerance in Patients With Chronic Heart Failure," was published online on August 25th and will appear in the September 19th issue in print.
Results of the trial demonstrated that EECP(R) therapy improves exercise capacity, relieves symptoms and improves quality of life for heart failure patients already receiving optimal medical therapy. Additional analysis presented in the report showed that patients with ischemic heart failure, i.e. caused by underlying atherosclerotic coronary artery disease, achieved greater benefit than those with non-ischemic heart failure.
VASOMEDICAL INC
[Stock Ticker Chart]
OTCBB:VASO
Updated: 11:04 ET
0.145 +0.015
Arthur Feldman, M.D., Ph.D., professor and chairman of the Department of Medicine, Jefferson Medical College, Thomas Jefferson University, and principal investigator for the PEECH trial noted, "Results of the PEECH trial, specifically the greater benefit observed in ischemic heart failure patients, are consistent with prior studies of EECP in patients with ischemic heart disease, including a randomized trial in angina, several case-series controlled studies, and a large patient registry. In stable, well-managed heart failure patients who remain symptomatic despite receiving guideline-recommended therapy, EECP can help by relieving symptoms, increasing activity levels and improving quality of life in this difficult-to-treat disease."
In a related article published simultaneously, researchers at the University of Florida College of Medicine reported that EECP therapy reduced arterial stiffness and decreased wasted cardiac energy in patients with long-standing coronary artery disease and ischemia. The report, entitled "Enhanced External Counterpulsation Treatment Improves Arterial Wall Properties and Wave Reflection Characteristics in Patients With Refractory Angina," illustrates important favorable effects EECP therapy achieves on blood vessels outside of the heart and reveals one of the mechanisms by which both angina and ischemic heart failure patients obtain benefit.
Thomas Glover, president and chief executive officer of Vasomedical stated, "The results of the PEECH trial are quite impressive. The data for the subset of patients with ischemic heart failure compares very favorably with other widely accepted invasive treatments such as resynchronization therapy, with considerably less risk and cost. We believe primary care physicians and cardiologists treating heart failure patients should strongly consider EECP therapy as an adjunct to other medically indicated therapies for heart failure. It should be a treatment option offered to every stable ischemic heart failure patient."
"PEECH adds to the growing body of evidence supporting the use of EECP therapy in patients with ischemic heart disease, e.g. angina and ischemic heart failure. Also, the significant findings by researchers at the University of Florida continue to illustrate the powerful physiologic effects of the therapy. In our view, EECP therapy has a very favorable benefit-to-risk ratio, is safe, noninvasive, and low-cost," added Thomas Glover.
About EECP(R) Therapy
EECP external counterpulsation therapy is typically given in 35 one-hour sessions over seven weeks. Patients recline on a contoured treatment table and their calves, lower thighs and upper thighs are wrapped in a pneumatic cuff set. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting and deflates the cuffs just before the next heartbeat. The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle and other organs and decreases the heart's workload, creating a greater oxygen supply for the heart muscle while lowering its need for oxygen.
About Vasomedical, Inc.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP equipment, treatment guidance and a staff training and equipment maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com. EECP is a registered trademark for Vasomedical's enhanced external counterpulsation systems.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports, including the ability of the Company to continue as a going concern. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Vasomedical, Inc. Thomas Glover/Thomas Fry, 516-997-4600 or Investor Relations: 516-997-4600 ext. 790 investorrelations@vasomedical.com
08/29/2006 15:09
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology
WESTBURY, N.Y.--(BUSINESS WIRE)---- EECP Therapy Benefits Patients with Mild-to-Moderate Heart Failure; is Most Effective for Treating Ischemic Heart Failure Patients
Vasomedical, Inc. (OTCBB: VASO.OB), a leader in the non-invasive treatment and management of cardiovascular diseases, announced today publication of the results of the PEECH trial (Prospective Evaluation of EECP in Congestive Heart Failure) in the Journal of the American College of Cardiology. The report, entitled "Enhanced External Counterpulsation Improves Exercise Tolerance in Patients With Chronic Heart Failure," was published online on August 25th and will appear in the September 19th issue in print.
Results of the trial demonstrated that EECP(R) therapy improves exercise capacity, relieves symptoms and improves quality of life for heart failure patients already receiving optimal medical therapy. Additional analysis presented in the report showed that patients with ischemic heart failure, i.e. caused by underlying atherosclerotic coronary artery disease, achieved greater benefit than those with non-ischemic heart failure.
VASOMEDICAL INC
[Stock Ticker Chart]
OTCBB:VASO
Updated: 11:04 ET
0.145 +0.015
Arthur Feldman, M.D., Ph.D., professor and chairman of the Department of Medicine, Jefferson Medical College, Thomas Jefferson University, and principal investigator for the PEECH trial noted, "Results of the PEECH trial, specifically the greater benefit observed in ischemic heart failure patients, are consistent with prior studies of EECP in patients with ischemic heart disease, including a randomized trial in angina, several case-series controlled studies, and a large patient registry. In stable, well-managed heart failure patients who remain symptomatic despite receiving guideline-recommended therapy, EECP can help by relieving symptoms, increasing activity levels and improving quality of life in this difficult-to-treat disease."
In a related article published simultaneously, researchers at the University of Florida College of Medicine reported that EECP therapy reduced arterial stiffness and decreased wasted cardiac energy in patients with long-standing coronary artery disease and ischemia. The report, entitled "Enhanced External Counterpulsation Treatment Improves Arterial Wall Properties and Wave Reflection Characteristics in Patients With Refractory Angina," illustrates important favorable effects EECP therapy achieves on blood vessels outside of the heart and reveals one of the mechanisms by which both angina and ischemic heart failure patients obtain benefit.
Thomas Glover, president and chief executive officer of Vasomedical stated, "The results of the PEECH trial are quite impressive. The data for the subset of patients with ischemic heart failure compares very favorably with other widely accepted invasive treatments such as resynchronization therapy, with considerably less risk and cost. We believe primary care physicians and cardiologists treating heart failure patients should strongly consider EECP therapy as an adjunct to other medically indicated therapies for heart failure. It should be a treatment option offered to every stable ischemic heart failure patient."
"PEECH adds to the growing body of evidence supporting the use of EECP therapy in patients with ischemic heart disease, e.g. angina and ischemic heart failure. Also, the significant findings by researchers at the University of Florida continue to illustrate the powerful physiologic effects of the therapy. In our view, EECP therapy has a very favorable benefit-to-risk ratio, is safe, noninvasive, and low-cost," added Thomas Glover.
About EECP(R) Therapy
EECP external counterpulsation therapy is typically given in 35 one-hour sessions over seven weeks. Patients recline on a contoured treatment table and their calves, lower thighs and upper thighs are wrapped in a pneumatic cuff set. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting and deflates the cuffs just before the next heartbeat. The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle and other organs and decreases the heart's workload, creating a greater oxygen supply for the heart muscle while lowering its need for oxygen.
About Vasomedical, Inc.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP equipment, treatment guidance and a staff training and equipment maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com. EECP is a registered trademark for Vasomedical's enhanced external counterpulsation systems.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports, including the ability of the Company to continue as a going concern. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Vasomedical, Inc. Thomas Glover/Thomas Fry, 516-997-4600 or Investor Relations: 516-997-4600 ext. 790 investorrelations@vasomedical.com
08/29/2006 15:09
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology
WESTBURY, N.Y.--(BUSINESS WIRE)---- EECP Therapy Benefits Patients with Mild-to-Moderate Heart Failure; is Most Effective for Treating Ischemic Heart Failure Patients
Vasomedical, Inc. (OTCBB: VASO.OB), a leader in the non-invasive treatment and management of cardiovascular diseases, announced today publication of the results of the PEECH trial (Prospective Evaluation of EECP in Congestive Heart Failure) in the Journal of the American College of Cardiology. The report, entitled "Enhanced External Counterpulsation Improves Exercise Tolerance in Patients With Chronic Heart Failure," was published online on August 25th and will appear in the September 19th issue in print.
Results of the trial demonstrated that EECP(R) therapy improves exercise capacity, relieves symptoms and improves quality of life for heart failure patients already receiving optimal medical therapy. Additional analysis presented in the report showed that patients with ischemic heart failure, i.e. caused by underlying atherosclerotic coronary artery disease, achieved greater benefit than those with non-ischemic heart failure.
VASOMEDICAL INC
[Stock Ticker Chart]
OTCBB:VASO
Updated: 11:04 ET
0.145 +0.015
Arthur Feldman, M.D., Ph.D., professor and chairman of the Department of Medicine, Jefferson Medical College, Thomas Jefferson University, and principal investigator for the PEECH trial noted, "Results of the PEECH trial, specifically the greater benefit observed in ischemic heart failure patients, are consistent with prior studies of EECP in patients with ischemic heart disease, including a randomized trial in angina, several case-series controlled studies, and a large patient registry. In stable, well-managed heart failure patients who remain symptomatic despite receiving guideline-recommended therapy, EECP can help by relieving symptoms, increasing activity levels and improving quality of life in this difficult-to-treat disease."
In a related article published simultaneously, researchers at the University of Florida College of Medicine reported that EECP therapy reduced arterial stiffness and decreased wasted cardiac energy in patients with long-standing coronary artery disease and ischemia. The report, entitled "Enhanced External Counterpulsation Treatment Improves Arterial Wall Properties and Wave Reflection Characteristics in Patients With Refractory Angina," illustrates important favorable effects EECP therapy achieves on blood vessels outside of the heart and reveals one of the mechanisms by which both angina and ischemic heart failure patients obtain benefit.
Thomas Glover, president and chief executive officer of Vasomedical stated, "The results of the PEECH trial are quite impressive. The data for the subset of patients with ischemic heart failure compares very favorably with other widely accepted invasive treatments such as resynchronization therapy, with considerably less risk and cost. We believe primary care physicians and cardiologists treating heart failure patients should strongly consider EECP therapy as an adjunct to other medically indicated therapies for heart failure. It should be a treatment option offered to every stable ischemic heart failure patient."
"PEECH adds to the growing body of evidence supporting the use of EECP therapy in patients with ischemic heart disease, e.g. angina and ischemic heart failure. Also, the significant findings by researchers at the University of Florida continue to illustrate the powerful physiologic effects of the therapy. In our view, EECP therapy has a very favorable benefit-to-risk ratio, is safe, noninvasive, and low-cost," added Thomas Glover.
About EECP(R) Therapy
EECP external counterpulsation therapy is typically given in 35 one-hour sessions over seven weeks. Patients recline on a contoured treatment table and their calves, lower thighs and upper thighs are wrapped in a pneumatic cuff set. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting and deflates the cuffs just before the next heartbeat. The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle and other organs and decreases the heart's workload, creating a greater oxygen supply for the heart muscle while lowering its need for oxygen.
About Vasomedical, Inc.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP equipment, treatment guidance and a staff training and equipment maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com. EECP is a registered trademark for Vasomedical's enhanced external counterpulsation systems.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports, including the ability of the Company to continue as a going concern. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Vasomedical, Inc. Thomas Glover/Thomas Fry, 516-997-4600 or Investor Relations: 516-997-4600 ext. 790 investorrelations@vasomedical.com
08/29/2006 15:09
VASO had a nice close up 7% yesterday at .14.
http://66.201.236.134/export/level2.jsp?symbol=vaso&=Get+Quote
I like where MAXM is asking 1.01 this a.m.; it would be nice to see the others back off and let this one roll. The results will be published on the 16th. Maybe VASO is getting set up for a stellar end of month run. There is no reason VASO can not see .25 in the coming weeks.
Good Trading!
VASO had a nice close up 7% yesterday at .14.
http://66.201.236.134/export/level2.jsp?symbol=vaso&=Get+Quote
I like where MAXM is asking 1.01 this a.m.; it would be nice to see the others back off and let this one roll. The results will be published on the 16th. Maybe VASO is getting set up for a stellar end of month run. There is no reason VASO can not see .25 in the coming weeks.
Good Trading!
VASO had a nice close up 7% yesterday at .14.
http://66.201.236.134/export/level2.jsp?symbol=vaso&=Get+Quote
I like where MAXM is asking 1.01 this a.m.; it would be nice to see the others back off and let this one roll. The results will be published on the 16th. Maybe VASO is getting set up for a stellar end of month run. There is no reason VASO can not see .25 in the coming weeks.
Good Trading!
VASO last .13
.135 x .14 RTBA
Get it before the trial results are published on the 16th.
VASO last .13
.135 x .14 RTBA
Get it before the trial results are published on the 16th.
Howdy! Just got back in from vacation. I see they tanked VASO while I was gone...LOL! I guess that means up from here.
VASO last .13
.135 x .14 RTBA
Stock Rancher Power Play JUST RELEASED!!!!!
VASO .14 x .15 (-11.76%) on 497,500.
Good Trading!
Stock Rancher Power Play
VASO .14 x .15 (-11.76%) on 497,500
Mark this post, here is the entry for a quick buck. Let's see if I can get 2 of 2 eom.
Good Trading!
Stock Rancher Power Play
WOW!!!! Look at L2 on VASO!!!!
http://66.201.236.134/export/level2.jsp?symbol=vaso&=Get+Quote
Looks like a gapper today. Another note, Cramer was talking wine companies last night and said he did not know of any niche companies. Heres one for the record: TSIX. They are a nich player in California and the best deal about being a shareholder is that you get free pit passes to the Indy 500 and get to have wine and cheese with the insiders; well worth the cheap 100 share block.
Good Trading!
OLD PR:
360 Global Wine Company Shareholders and Tuscan Club Members Invited to Second IndyCar Race of the Season
Thursday March 30, 5:30 pm ET
SONOMA, Calif., March 30, 2006 (PRIMEZONE) -- 360 Global Wine Company (OTC BB:TSIX.OB - News), a California based company that engages in the marketing and distribution of wines and wine-related products, and the Company's Viansa Winery & Italian Marketplace, extend an invitation to all shareholders and to members of Viansa's Tuscan Club to attend the second race of the 2006 IndyCar season.
This race will take place on Sunday, April 2 at 3:30 PM at the Grand Prix of St. Petersburg in St. Petersburg, Florida. The race will be nationally televised on ESPN.
As previously announced, Viansa Winery & Italian Marketplace is proud to be sponsoring the Vision Racing Team for this 2006 IndyCar season. Viansa's sponsorship is an important component of building Viansa's national branding among American wine consumers. 360 stockholders and members of Viansa's Tuscan Club interested in attending the event as guests of the Company should contact Denise Taranto at 203-869-6313.
Additional information on the event can be found at http://www.indyracing.com and http://www.gpstpete.com.
About 360 Global Wine Company
360 Global Wine Company (http://www.360wines.com), based in Sonoma, California, sells wines and wine-related products through direct sales channels and independent distributors to grocery stores, wine shops, and restaurants. 360 Global's holdings include the Viansa Winery & Italian Marketplace and the Kirkland Ranch Winery. Viansa Winery & Italian Marketplace (http://www.viansa.com), the 2006 Winner of ``The Best Wine Country Experience in Napa and Sonoma Valleys,' is a destination winery at the entrance to the Sonoma Valley Wine Country, created as a way to share with visitors from around the world the Italian heritage's love of good food and premium wine with exquisite events focusing on the authentic wine country lifestyle.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the ``Act'). In particular, when used in the preceding discussion, the words ``plan,' ``confident that,' ``believe,' ``scheduled,' ``expect,' or ``intend to,' and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to the company's access to additional capital, competitive factors, the company's ability to consummate its acquisition strategy, consumer acceptance of the company's products and dependence on key management.
Contact:
360 Global Wine Company
Corporate Information:
Joel Shapiro, President
(203) 869-6313
jakes@360wines.com
Event Information and ticketing:
Denise Taranto
(203) 869-6313
deniset@360wines.com
SSP, Nasdaq....Goldman.....and you pick it! It has to hit $2+...LOL! Too bad that I have business today, I get the feeling VASO will pop later in the session like ACTC did. I did not bet the farm here, only a few hundred in mad money. Thanks for the heads up. See everyone later this evening.
Good Trading!
Bought some VASO,
I hope I did'nt hex it....LOL!